Amylyx Pharmaceuticals Expands Pipeline with New GLP-1 Receptor Antagonist Candidate AMX0318
AMLX has more than doubled off its 52-week low of $2.6.
Summary
Amylyx Pharmaceuticals announced the selection of AMX0318, a long-acting GLP-1 receptor antagonist, as a development candidate for post-bariatric hypoglycemia and other rare diseases, triggering a $4 million milestone payment.
Key Events · Product Development and Regulatory · AMLX
-
New Development Candidate Selected
Amylyx selected AMX0318, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist, as a development candidate for post-bariatric hypoglycemia and other rare diseases.
-
Milestone Payment Triggered
The selection of AMX0318 triggered a $4 million milestone payment to Gubra A/S, with potential for over $50 million in future development and commercialization milestones plus mid-single digit royalties.
-
Pipeline Advancement
AMX0318 is expected to advance into IND-enabling studies in 2026, with an Investigational New Drug (IND) submission targeted for 2027.
Analysis · AMLX · Life Sciences
This announcement marks a positive expansion of Amylyx's pipeline into new therapeutic areas with a novel GLP-1 receptor antagonist. While AMX0318 is an early-stage preclinical candidate, its selection demonstrates ongoing R&D productivity and the potential for future value creation through significant milestone payments and royalties. The company's collaboration with Gubra A/S and the planned progression to IND-enabling studies in 2026 indicate a clear development path for this new asset, diversifying its portfolio beyond neurodegenerative diseases and potentially strengthening its long-term growth prospects.
At the time of this filing, AMLX was trading at $12.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $2.60 to $16.96. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.